Study of EZN-2208 Pediatric Patients With Solid Tumors
Status:
Unknown status
Trial end date:
2012-08-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to find the highest tolerable dose of EZN-2208
that can be given to pediatric patients with Relapsed or Refractory Solid Tumors. The safety
of the study drug and its effect on the disease will also be studied.